Genmab A+s

Genmab B.v.

Roche Palo Alto LLC

Biontech Se

Aran Frank Labrijn

Paul Parren

Janine Schuurman

Jan Van De Winkel

Joost J Neijssen

Joyce Meesters

Edward Norbert Van Den Brink

Bart De Goeij

Tom Vink

Patrick Van Berkel

Rene Hoet

Frank Beurskens

Rob N De Jong

Ewald T J Van Den Bremer

Stefan Seeber

David Satijn

Ole Baadsgaard

Ralf Schumacher

Arnout F Gerritsen

Yvo Graus

Elsie M Eugui

Martin Lanzendoerfer

Martine Van Vugt

Frank Rebers

Simone De Haij

Thilo Riedl

Ugur Sahin

Rik Rademaker

Isil Altintas

Alexander Muik

Willem Karel Bleeker

Stefan Loverix

Michael J Gramer

Ignace Lasters

Friederike Gieseke

Mark Chiu

Sandra Verploegen

Adam Zwolak

Thomas C Nesspor

Simone Oostindie

David P E Satijn

Anthony A Armstrong

Marijn Van Der Neut Kolfschoten

Esther Cornelia Wilhelmina Breij

Maria Elena Fuentes

Bart-Jan De Kreuk

Richard Hibbert

Joseph Endl

Lars Guelen

Rob Aalberse

Sina Fellermeier-kopf

Amitava Kundu

Muriel Van Kampen

Patrick Priem

Werner L Vos

Frank Everhardus Martinus Rebers

Marijn Van Der Neut Kolfschote

Kristin Strumane

Ivan Kuzmanov

Patricia Garrido Castro

Jordan Blum

Andreea Ioan

Kristina Nürmberger

Rene M A Hoet

Arjen Vlug

Jan Van Winkel

Matthew Bunce

Jau Van De Winkel

Lgnace Laster

Ewald Van Den Bremer

Karsten Beckmann

Claudia Paulmann

Richard G Hibbert

Rene M Hoet

Edward N Brink

Ewald Van Bremer

Joyce I Meesters

René Hoet

Ewald TJ Van Den Bremer

The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.

Binding agents binding to EpCAM and CD137

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

Antibody variant combinations and uses thereof

The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

Method for producing a controlled mixture of two or more different antibodies

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

Antibody variants and uses thereof

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Humanized or chimeric CD3 antibodies

Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

Bispecific antibodies against HER2 and CD3

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against c-Met

The present invention relates to an in vitro method for production of heterodimeric proteins.

Production of heterodimeric proteins

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Inert format

The present invention relates to dimeric proteins comprising amino acids at three different positions which are different from those present in a human IgG1. Six of said dimeric proteins are capable of forming a hexameric structure in solution.

Dimeric protein with triple mutations

Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against HER2

The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.

Bispecific antibodies and methods for production thereof

Growing community of inventors

Nigtevecht, Netherlands

Aran Frank Labrijn